|
|
|
|
Дата |
|---|
| 19:26 |
| 14.05.2026 |
| 13.05.2026 |
| 12.05.2026 |
| 11.05.2026 |
| 08.05.2026 |
| 07.05.2026 |
| 06.05.2026 |
| 05.05.2026 |
| 04.05.2026 |
Bid | Ask |
Open |
Min | Max |
Last |
Legal close |
Avg |
Оборот |
Кол-во сделок |
|---|---|---|---|---|---|---|---|
|
4.89
|
5.02
|
4.39
|
4.30
|
5.32
|
4.96
|
|
|
278 023.80
|
718.00
|
|
5.47
|
6.10
|
6.48
|
6.28
|
6.77
|
6.71
|
|
|
43 781.92
|
175.00
|
|
6.41
|
6.59
|
6.06
|
6.00
|
6.605
|
6.60
|
|
|
45 561.19
|
184.00
|
|
5.90
|
6.15
|
5.575
|
5.575
|
6.11
|
6.09
|
|
|
67 507.09
|
178.00
|
|
5.30
|
5.96
|
5.45
|
5.35
|
5.73
|
5.73
|
|
|
33 717.87
|
226.00
|
|
5.27
|
5.96
|
5.59
|
5.34
|
5.59
|
5.41
|
|
|
61 056.12
|
188.00
|
|
5.20
|
5.89
|
5.515
|
5.415
|
5.67
|
5.57
|
|
|
22 774.30
|
137.00
|
|
5.18
|
5.89
|
5.35
|
5.35
|
5.895
|
5.88
|
|
|
59 885.96
|
146.00
|
|
5.03
|
5.55
|
5.45
|
5.285
|
5.52
|
5.465
|
|
|
39 986.32
|
142.00
|
|
5.10
|
5.63
|
5.45
|
5.27
|
5.50
|
5.27
|
|
|
29 769.51
|
133.00
|
Aardvark Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. Its lead product candidate is the ARD-101, an oral gut-restricted small-molecule agonist of certain targeting bitter taste receptors expressed in the gut lumen that is in Phase III clinical trial for hyperphagia associated with Prader-Willi Syndrome, as well as in Phase II clinical trial for hyperphagia associated with acquired hypothalamic obesity resultant from treatment of craniopharyngioma, including surgery or radiation.
It also developing ARD-201, which is in Phase I clinical trial for the treatment of obesity. The company was incorporated in 2017 and is based in San Diego, California.
Показать все Скрыть